高截留分子量超滤膜在临床中的应用.ppt
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_1.gif)
![资源得分’ title=](/images/score_05.gif)
《高截留分子量超滤膜在临床中的应用.ppt》由会员分享,可在线阅读,更多相关《高截留分子量超滤膜在临床中的应用.ppt(43页珍藏版)》请在淘文阁 - 分享文档赚钱的网站上搜索。
1、crrt高截留分子量超滤膜在临床中的应用高截留分子量超滤膜在临床中的应用112/21/20222基本概念高截留分子量超滤膜高截留分子量超滤膜在临床中的应用内容目录12/21/20223截留分子量截留分子量截留分子量截留分子量CO是指对有孔材料孔径大小的一种描述。在能自由通过某种有孔材料的分子中最大分子的分子量即为该材料的截留分子量。大于截留分子量的分子,被材料截留;小于截留分子量的分子,则可自由通过。一般滤器膜的截留分子量分子的筛选系数为0.1,即通过滤器膜能力为10%的分子的分子量定义为截留分子量。DEFINITION:The cut-off point of a solute for an
2、y membrane is a sieving coefficient of 0.1.This means that 10%of the molecules will pass and 90%will not pass.12/21/20224筛选系数-SC筛选系数SC(seiving coeffcient)为超滤液中溶质浓度与滤器前血浆溶质浓度比值,是溶质通过滤器膜能力的一个定量指标SC越高,表明CRRT治疗清除的 溶质越多,SC接近1,提示溶质近乎可自由通过滤器膜滤器膜的性质会影响SC值SIEVING COEFFICIENT1.00 05600 inulin11800 b2-m21000 R
3、BP44000 orosomucoide54000 a1 AT66500albuminMOLECULAR WEIGHT=SOLUTE SIZEDEFINITION:The cut-off point of a solute for any membrane is a sieving coefficient of 0.1.This means that 10%of the molecules will pass and 90%will not pass.0.560 ureaCut-off pointO.1筛选系数与截留分子量筛选系数与截留分子量Solute Classes by Molecula
4、r WeightDaltons Inflammatory Mediators(1,200-50,000)“small”“middle”“large”crrt高截留分子量超滤膜高截留分子量超滤膜RR-AB-34 Jan 2011New functional membrane with defined larger pore sizeHCO membrane 0,01 m 0,02 m 0,09 m 0,30 m:pore diameterhigh fluxhigh cut-off*protein separation membraneplasma separation membraneVaria
5、tion of membrane pore sizeElectron micrographs of inner membrane surfacesieving coefficient100100010000100000100000000.20.40.60.81Molecular weight DClassical Filter30 kD human kidneyhigh cut-offHigh Cut-Off Hemofilter Molecular Weight DaStandard HighFluxHigh Cut-OffHF,UF=1L/h,t=2hMedian,25th-75th pe
6、rcentiles)ICM(2002)28:651-655HCO Membrane with increased permeability for inflammatory mediatorsmembrane characteristics crrt高截留分子量超滤膜的临床应用高截留分子量超滤膜的临床应用12HCO treatment reduces significantly inflammatory mediator plasma levels高截留分子量超滤膜的临床应用IL-6 in PROWESSNon-survivorsSurvivorsKinasewitz et al,Crit C
7、are 2004PROWESS(Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis)StudyAt study entry,evaluated IL-6 was present in 98.5%patentsLimited Effect of“Standard”CRRT on Plasma Inflammatory Mediator LevelsHerring et al,Kidney Blood Press Res 2003Course of IL-6 plasma level during
8、treatment with septeX/HCOIntensive Care Med 2003;29:1989-95N=24 pts CVVHSubstantial Reduction of Plasma IL-6 LevelsInterleukin-6 plasma valuesCrit Care Med.2006;34:2099-04.N=10 pts CVVHN=20 pts CVVHIL-6 ClearancemL/minSieving coefficient:Morgera S,Bellomo R et al.Crit Care Med.2006;34:2099-040.00.01
9、 10.00.01 10.00.00 00.90.93 30.90.93 30.80.84 4CVVHUF-rate 2.5L/hRecent HPHF Studies in Sepsis:Clearance rates for IL-6 were significantly higher in the high cutoff hemofiltration group(p .0001).Cellular immunomodulation through HCO treatment高截留分子量超滤膜的临床应用Muret et alShock 2000 Hoffmann et alKidney I
10、nt.1995Heidecke et alAm J Surg.1999T-Lymhocyte Proliferation is Reduced in SepsisMonocyte phagocytosis is elevated in SepsisSpark JI,Scott DJ.Br J Surg.2001;88:1583-9.Simms HH,DAmico R.Blood.1994;83:1398-407Cellular immunomodulationHuman sepsis studies:HCO treatment restores lymphocyte proliferation
11、 in septic patients NDT,2003;18:2570-6.N=28 pts CVVH与HCO可以滤除淋巴细胞增殖的阻滞物质有关HCO treatment reduces monocyte phagocytosis rate of septic patientsNephron Clin Pract.2003;94:75-80 CVVHClinical benefits through HCO treatment高截留分子量超滤膜的临床应用Norepinephrine requirement is reduced with HCO Crit Care Med.2006;34:2
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 截留 分子量 超滤膜 临床 中的 应用
![提示](https://www.taowenge.com/images/bang_tan.gif)
限制150内